Kissei Pharmaceutical Co Ltd (JP:4547)

:4547

4547

Kissei Pharmaceutical Co

RESEARCH TOOLSreports

Want to see JP:4547 full AI Analyst Report?

Kissei Pharmaceutical Co (4547) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4547 Analyst Ratings

Moderate Buy

1 Buy

2 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Kissei

Pharmaceutical Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4547 Stock 12 Month Forecast

Average Price Target

¥4,220.00

▼(-8.46% Downside)

Based on 3 Wall Street analysts offering 12 month price targets for Kissei Pharmaceutical Co in the last 3 months. The average price target is ¥4,220.00 with a high forecast of ¥4,800.00 and a low forecast of ¥3,760.00. The average price target represents a -8.46% change from the last price of ¥4,610.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3759":"¥3,759","4022":"¥4,022","4285":"¥4,285","4548":"¥4,548","4811":"¥4,811"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4800,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥4.80K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4220,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥4.22K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3760,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥3.76K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3759,4022,4285,4548,4811],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3810,3886.153846153846,3962.3076923076924,4038.4615384615386,4114.615384615385,4190.7692307692305,4266.923076923077,4343.076923076923,4419.2307692307695,4495.384615384615,4571.538461538462,4647.692307692308,4723.846153846154,{"y":4800,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3810,3841.5384615384614,3873.076923076923,3904.6153846153848,3936.153846153846,3967.6923076923076,3999.230769230769,4030.769230769231,4062.3076923076924,4093.846153846154,4125.384615384615,4156.923076923077,4188.461538461538,{"y":4220,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3810,3806.153846153846,3802.3076923076924,3798.4615384615386,3794.6153846153848,3790.769230769231,3786.923076923077,3783.076923076923,3779.230769230769,3775.3846153846152,3771.5384615384614,3767.6923076923076,3763.846153846154,{"y":3760,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4080.499,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3872.852,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4254.343,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4177.078,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4165.703,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3940.529,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4547.518,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4552.413,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4527.938,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4758.006,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4810,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4320,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3810,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target¥4,800

Average Price Target¥4,220

Lowest Price Target¥3,760

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Nomura

Not Ranked

Nomura

¥5,600→¥4,100

Hold

-11.06%

Downside

Downgraded

06/05/26

Kissei Pharmaceutical Co (KSPHF) was downgraded to a Hold Rating at Nomura

Unknown Analyst

SBI Securities

Not Ranked

SBI Securities

¥3,760

Hold

-18.44%

Downside

Reiterated

06/04/26

Kissei Pharmaceutical Co (KSPHF) Receives a Hold from SBI Securities

Miyabi Yamakita

Jefferies

¥5,400→¥4,800

Buy

4.12%

Upside

Reiterated

05/25/26

Kissei Pharmaceutical Co (KSPHF) Receives a Buy from Jefferies

Unknown Analyst

Daiwa

Not Ranked

Daiwa

¥5,500

Buy

19.31%

Upside

Reiterated

01/29/26

Kissei Pharmaceutical Co (KSPHF) Receives a Buy from Daiwa

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

¥5,000

Hold

8.46%

Upside

Reiterated

12/03/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Nomura

Not Ranked

Nomura

¥5,600→¥4,100

Hold

-11.06%

Downside

Downgraded

06/05/26

Kissei Pharmaceutical Co (KSPHF) was downgraded to a Hold Rating at Nomura

Unknown Analyst

SBI Securities

Not Ranked

SBI Securities

¥3,760

Hold

-18.44%

Downside

Reiterated

06/04/26

Kissei Pharmaceutical Co (KSPHF) Receives a Hold from SBI Securities

Miyabi Yamakita

Jefferies

¥5,400→¥4,800

Buy

4.12%

Upside

Reiterated

05/25/26

Kissei Pharmaceutical Co (KSPHF) Receives a Buy from Jefferies

Unknown Analyst

Daiwa

Not Ranked

Daiwa

¥5,500

Buy

19.31%

Upside

Reiterated

01/29/26

Kissei Pharmaceutical Co (KSPHF) Receives a Buy from Daiwa

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

¥5,000

Hold

8.46%

Upside

Reiterated

12/03/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kissei Pharmaceutical Co

3 Months

Miyabi YamakitaJefferies

Success Rate

1/3 ratings generated profit

Average Return

+2.07%

Copying Miyabi Yamakita's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of +2.07% per trade.

1 Year

Miyabi YamakitaJefferies

Success Rate

1/3 ratings generated profit

Average Return

-3.37%

Copying Miyabi Yamakita's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -3.37% per trade.

2 Years

Miyabi YamakitaJefferies

Success Rate

1/3 ratings generated profit

Average Return

-5.03%

Copying Miyabi Yamakita's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -5.03% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4547 Analyst Recommendation Trends

Rating

Feb 26

Mar 26

Apr 26

May 26

Jun 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4547 has received 4 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 4547 average Analyst price target in the past 3 months is 4,220.00.

Each month's total comprises the sum of three months' worth of ratings.

4547 Financial Forecast

4547 Earnings Forecast

Next quarter’s earnings estimate for 4547 is ¥55.99 with a range of ¥50.18 to ¥64.70. The previous quarter’s EPS was ¥66.77. 4547 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 4547 has Performed in-line its overall industry.

4547 Sales Forecast

Next quarter’s sales forecast for 4547 is ¥22.57B with a range of ¥21.34B to ¥23.50B. The previous quarter’s sales results were ¥24.77B. 4547 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 4547 has Performed in-line its overall industry.

4547 Stock Forecast FAQ

What is JP:4547’s average 12-month price target, according to analysts?

Based on analyst ratings, Kissei Pharmaceutical Co Ltd’s 12-month average price target is 4,220.00.

What is JP:4547’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for JP:4547, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Kissei Pharmaceutical Co Ltd a Buy, Sell or Hold?

Kissei Pharmaceutical Co Ltd has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 2 hold ratings and 0 sell ratings.

What is Kissei Pharmaceutical Co Ltd’s share price target?

The average share price target for Kissei Pharmaceutical Co Ltd is 4,220.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ¥4,800.00 ,and the lowest forecast is ¥3,760.00. The average share price target represents -8.46% Decrease from the current price of ¥4,610.

What do analysts say about Kissei Pharmaceutical Co Ltd?

Kissei Pharmaceutical Co Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of Kissei Pharmaceutical Co Ltd?

To buy shares of JP:4547, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Kissei Pharmaceutical Co (4547) Stock Forecast & Price Target

4547 Analyst Ratings

4547 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Kissei Pharmaceutical Co

4547 Analyst Recommendation Trends

4547 Financial Forecast

4547 Earnings Forecast

4547 Sales Forecast

4547 Stock Forecast FAQ

Detailed List of Analyst Forecasts